Ophthalmologists discuss how advanced imaging, MIGS, and home monitoring are reshaping decision-making in complex glaucoma ...

It's one of the most common causes of vision loss, and one of the easiest to overlook. Glaucoma symptoms develop so gradually ...

There's fresh hope for early detection and new treatments of glaucoma, a group of eye diseases that have devastating effects ...

AND JESS, YOU SAY THIS COULD BE A GAME CHANGER. YOU KNOW, IT REALLY CAN. ABOUT 3 MILLION AMERICANS HAVE GLAUCOMA AND THIS NEW TREATMENT IS BASICALLY AN IMPLANTABLE DRUG FOR THE EYE. AND DOCTORS SAY IT ...

Developed by Glaukos, the iDose TR (travoprost intraocular implant) 75 mcg is a new, FDA-approved treatment that is designed ...

Please provide your email address to receive an email when new articles are posted on . Glaucoma-related ocular surface disease is a significant and often underdiagnosed ocular comorbidity that can ...

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years. Neil Minkoff, MD: Where do we see glaucoma therapy going in the next 24 to 36 months, due to ...

A new study in mice has identified new treatment targets for glaucoma, including preventing a severe pediatric form of glaucoma, as well as uncovering a possible new class of therapy for the most ...

Please provide your email address to receive an email when new articles are posted on . More than half of all patients treated with glaucoma medications have ocular surface disease, which ...

Glaucoma is a devastating eye disease that currently affects more than 3 million Americans. By the year 2050, data shows the number of cases is projected to surge to more than 6 million cases. This is ...

Glaucoma creeps in without pain or obvious symptoms, slowly damaging your optic nerve. Regular eye exams and early detection ...

Macular degeneration and glaucoma can both lead to vision loss. However, macular degeneration tends to affect central vision while glaucoma affects side vision. The causes and treatment are also ...